RYTM - Rhythm Pharmaceuticals, Inc. News

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 38.46% on

prnewswire.com

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inve

Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weig

IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric pa

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Mana

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global com

David Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CEO David Meeker sold 50,000 shares of

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day tradin

seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Confere

10 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endoc

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paed

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on

Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today

Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on

Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with

247wallst.com

Here Are Friday’s Top Wall Street Analyst Research Calls: Baozun, Commerce Bancshares, Element Solut

NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts wer

Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM

Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)

fool.com

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New

Duquesne Family Office has beefed up its healthcare holdings.

Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company foc

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquir

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Com

fool.com

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Be

Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competit

seekingalpha.com

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm

marketbeat.com

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts

Rhythm Pharmaceuticals NASDAQ: RYTM is expanding commercialization of its rare-disease obesity treat

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesit

JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported second-quarter 2026 global net product sales of $71.3

Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform

Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market O

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm

seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

marketbeat.com

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 m

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call

Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earning

zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zac

Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the a

Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In

Eleven patients with acquired HO were enrolled in the ongoing, open-label trial. Key preliminary fin

JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Targe

JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with

Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Se

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy

Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual Meeti

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

Why Is Rhythm Pharma Stock Jumping Today?

Rhythm Pharma Phase 2 data showed improvements in BMI, body composition, hunger symptoms, and behavi

Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh

Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06%

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI o

Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On Jun

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algor

"Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform